Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
|Videos|January 17, 2014
The Utility of the Myriad myRisk Hereditary Cancer Test
Author(s)Elizabeth Garner, MD, MPH
Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the Myriad myRisk Hereditary Cancer Test.
Advertisement
Clinical Pearls
Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the Myriad myRisk Hereditary CancerTMTest.
- MyRisk is a genetic test that looks for mutations in 25 genes that are known to be associated with significantly elevated risk for cancer
- There are eight major cancers the test can detect, including breast cancer, ovarian cancer, melanoma, and endometrial cancer.
- The test allows physicians to increase the rate of detection for individuals that have mutations or who have hereditary cancer syndromes
Advertisement
Related to this article
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
4
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
5